1-7 of 7
Yajuan Qin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

David M. Kurtz, Gregory Hogan, Andre Schultz, Jacob J. Chabon, Ash A. Alizadeh, Karin Havenith, Sara Samari, Tim Kopotsha, Luqiang Wang, Yajuan Qin, Ying Wang, Serafino Pantano
Journal: Blood
Blood (2023) 142 (Supplement 1): 3133.
https://doi.org/10.1182/blood-2023-179977
Published: 2023
Journal Articles

A Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination with Other Anticancer Agents in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (LOTIS-7)

Brian T. Hess, Graham P. Collins, Melhem Solh, Mitul Gandhi, Ying Wang, Yajuan Qin, Eric Yu, Pier Luigi Zinzani
Journal: Blood
Blood (2022) 140 (Supplement 1): 12079–12080.
https://doi.org/10.1182/blood-2022-163277
Published: 2022
Journal Articles

Identification of Predictive Biomarkers for Response of R/R DLBCL Patients Treated with Loncastuximab Tesirine Using Low Pass Whole-Genome Sequencing (WGS)

Francesco Vallania, Victoria Cheung, Michael D. Zamba, Joyce Liu, Amit Pasupathy, Hayley Donnella, Mitch Bailey, Maggie Louie, Jimmy Lin, Karin Havenith, Yajuan Qin, Serafino Pantano, Jens Wuerthner, Patrick H van Berkel
Journal: Blood
Blood (2022) 140 (Supplement 1): 3551–3552.
https://doi.org/10.1182/blood-2022-168993
Published: 2022
Journal Articles

Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial

Juan Pablo Alderuccio, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Matthew A. Lunning, Brian T. Hess, Pier Luigi Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Mehdi Hamadani, Brad S. Kahl, David Ungar, Turk Kilavuz, Eric Yu, Yajuan Qin, Paolo F. Caimi
Journal: Blood
Blood (2021) 138 (Supplement 1): 3575.
https://doi.org/10.1182/blood-2021-148730
Published: 2021
Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Clinical Trials & Observations
Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl
Journal: Blood
Blood (2021) 137 (19): 2634–2645.
https://doi.org/10.1182/blood.2020007512
Published: 2021
Includes: Supplemental data
Journal Articles

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Paolo F Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, MD, Kirit M. Ardeshna, Mehdi Hamadani, MD, Brian T. Hess, MD, Brad S. Kahl, MD, John A. Radford, MD FMedSci, Melhem Solh, MD, Anastasios Stathis, MD, Pier Luigi Zinzani, MD, Jay Feingold, David Ungar, Yajuan Qin, Shui He, Carmelo Carlo-Stella, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–37.
https://doi.org/10.1182/blood-2020-137524
Published: 2020
Journal Articles

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Carmelo Carlo-Stella, MD, Pier Luigi Luigi Zinzani, MD, Brad S. Kahl, MD, Paolo F Caimi, MD, Melhem Solh, MD, William Townsend, MRCP,MDFRCPath, Anastasios Stathis, MD, Elizabeth H. Cull, MD, Mehdi Hamadani, MD, Alexander I. Spira, PhD MD FACP, Jay Feingold, MD PhD, David Ungar, MD, Shui He, PhD, Yajuan Qin, John Radford
Journal: Blood
Blood (2019) 134 (Supplement_1): 757.
https://doi.org/10.1182/blood-2019-128401
Published: 2019